Loading…
Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma
Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT0294...
Saved in:
Published in: | Allergy (Copenhagen) 2023-08, Vol.78 (8), p.2157-2167 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL‐4/IL‐13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6–11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen‐specific IgE ≥0.35kU/L).
Methods
Annualized severe exacerbation rates (AER) and changes in pre‐bronchodilator (Pre‐BD) forced expiratory volume in one second (FEV1), percent‐predicted pre‐BD FEV1 (ppFEV1), and Asthma Control Score (ACQ)‐7 were assessed during the treatment period.
Results
350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab versus placebo significantly reduced AER in patients with (0.24 vs. 0.62, relative risk reduction [RRR]: 62% [95% CI, 39–76], P |
---|---|
ISSN: | 0105-4538 1398-9995 |
DOI: | 10.1111/all.15743 |